Bosh sahifaI9DN • FRA
add
Arbutus Biopharma Corp
Yopilish kursi
2,86 €
Kunlik diapazon
2,92 € - 2,92 €
Yillik diapazon
2,45 € - 4,22 €
Bozor kapitalizatsiyasi
679,75 mln USD
Oʻrtacha hajm
259,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,57 mln | -26,62% |
Joriy xarajat | 8,43 mln | 65,30% |
Sof foyda | -12,53 mln | 35,11% |
Sof foyda marjasi | -796,19 | 11,57% |
Har bir ulushga tushum | -0,10 | 38,71% |
EBITDA | -15,34 mln | 23,94% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 122,62 mln | -2,68% |
Jami aktivlari | 131,71 mln | -8,79% |
Jami passivlari | 34,34 mln | -10,53% |
Umumiy kapital | 97,37 mln | — |
Tarqatilgan aksiyalar | 191,48 mln | — |
Narxi/balansdagi bahosi | 5,61 | — |
Aktivlardan daromad | -28,79% | — |
Kapitaldan daromad | -36,08% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -12,53 mln | 35,11% |
Operatsiyalardan naqd pul | -10,32 mln | 40,35% |
Sarmoyadan naqd pul | 13,41 mln | -39,66% |
Moliyadan naqd pul | 1,42 mln | -62,67% |
Naqd pulning sof oʻzgarishi | 4,48 mln | -48,78% |
Boʻsh pul | -10,96 mln | -18,93% |
Haqida
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Tashkil etilgan
2007
Sayt
Xodimlar soni
44
